

[¹²⁵I]- STROMAL CELL-DERIVED FACTOR 1 ALPHA (HUMAN, RECOMINANT)

Product Number: NEX346

CXCL12
[¹²⁵I]-SDF-1α

LOT SPECIFIC INFORMATION

CALCULATED AS OF: 18-Dec-2023

LOT NUMBER: IF11940

SPECIFIC ACTIVITY: 81.4 TBq/mmol
2200.0 Ci/mmol
10.2 MBq/μg
275 μCi/μg

CONCENTRATION: 1.46 MBq/ml
39.5 μCi/ml

RADIOCHEMICAL PURITY: ≥ 95%

MOLECULAR WEIGHT: ~8000

PACKAGING: [¹²⁵I]-SDF-1α is in a solution containing 0.05M sodium acetate, 5% sucrose, 0.25% BSA, at pH 4.2. It is shipped on dry ice.

STABILITY AND STORAGE: [¹²⁵I]-SDF-1α should be stored at -20°C or lower. Under these conditions the product is stable and usable for at least six weeks after fresh lot date. Aliquoting is recommended to avoid multiple freeze/thaw cycles of vial contents.

SPECIFIC ACTIVITY: The initial specific activity of [¹²⁵I]-SDF-1α is 2200 Ci/mmol (81 TBq/mmol), 275μCi/μg (10.2MBq/μg). Preparative HPLC separates unlabeled SDF-1α from [¹²⁵I]-SDF-1α. Upon decay, [¹²⁵I]-SDF-1α undergoes decay catastrophe and the specific activity remains constant with time. However, it is not known what molecular fragments are generated from the decay event or what functional activity these fragments may have in different assays. References on ¹²⁵I decay and decay catastrophe of ¹²⁵I labeled compounds are available.¹⁻⁵

RADIOCHEMICAL PURITY: Initially less than 5% unbound iodide as determined by reverse phase HPLC chromatography.

PREPARATIVE PROCEDURE: Human recombinant SDF-1α, obtained from PeproTech, Inc., Rocky Hill, NJ, is radioiodinated with no carrier added ¹²⁵I using a lactoperoxidase procedure and is purified by reversed phase HPLC. This method predominantly labels tyrosine residues.

AVAILABILITY: [¹²⁵I]-SDF-1α is routinely available from stock and is prepared fresh and packaged for shipment on the third Monday of each month. Please inquire for larger package sizes.

APPLICATIONS: SDF-1α acts at the CXCR4 receptor. [¹²⁵I]-SDF-1α competes with SDF-1α in CXCR4

Package Size Information

Package Size as of 19-Jan-2024	Volume
185 kBq 5 μCi	0.20 ml
925 kBq 25 μCi	1.00 ml

APPLICATIONS: SDF-1 α acts at the CXCR4 (usin or LESTR) receptor. ¹²⁵I-SDF-1 α competes with SDF-1 α in CXCR4 receptor binding assays.⁷

HAZARD WARNING: This product contains a chemical (s) known to the state of California to cause cancer. This product also contains a component which is harmful by contact, ingestion or inhalation. It is irritating to the eyes and is toxic and flammable. Target organs are the central nervous system, respiratory system, kidneys and liver.

RADIATION UNSHIELDED: 280mR/hr/mCi at vial surface.

REFERENCES:

1. Doyle, V.M., Buhler, F.R., Burgisser, E., *Eur. J. Pharm.* 99 353 (1984).
2. Schmidt, J., *J. Biol. Chem.* 259 1160 (1984).
3. Loring, R.H., Jones, S.W., Matthews-Bellinger, J., Salpeter, M.M., *J. Biol. Chem.* 257 1418 (1982).
4. Berridge, M.S., Jiang, V.W., Welch, M.J., *Rad. Res.* 82 467 (1980).
5. Charlton, D.E., *Rad. Res.* 107 163 (1986).
6. Bleul, C.C., Wu, L., Hoxie, J.A., Springer, T.A., Mackay, C.R., *Proc. Natl. Acad. Sci. USA* 94 1925-1930 (1997).
7. Hesselgesser, J., Halks-Miller, M., DelVecchio, V., Peiper, S.C., Hoxie, J., Kolson, D.L., Taub, D., Horuk, R., *Current Biology* 7 112-121 (1997).

IODINE-125 DECAY CHART HALF LIFE=60 days

Radiations: Gamma 35.5 keV (7%), X-ray K alpha 27 KeV (112%), K beta 31 keV (24%)

DAYS	0	2	4	6	8	10	12	14	16	18
0	1.000	.977	.955	.933	.912	.891	.871	.851	.831	.812
20	.794	.776	.758	.741	.724	.707	.691	.675	.660	.645
40	.630	.616	.602	.588	.574	.561	.548	.536	.524	.512
60	.500	.489	.477	.467	.456	.445	.435	.425	.416	.406
80	.397	.388	.379	.370	.362	.354	.345	.338	.330	.322
100	.315	.308	.301	.294	.287	.281	.274	.268	.262	.256
120	.250	.244	.239	.233	.228	.223	.218	.213	.208	.203

To obtain the correct radioactive concentration or amount for a date before the calibration date: divide by the decay factor corresponding to the number of days before the calibration date. To obtain the correct radioactive concentration or amount for a date after the calibration date: multiply by the decay factor corresponding to the number of days after the calibration date.

The information provided in this document is valid for the specified lot number and date of analysis. This information is for reference purposes only and does not constitute a warranty or guarantee of the product's suitability for any specific use. Revvity, Inc., its subsidiaries, and/or affiliates (collectively, "Revvity") do not assume any liability for any errors or damages arising from the use of this document or the product described herein. REVVITY EXPRESSLY DISCLAIMS ALL WARRANTIES, INCLUDING WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, REGARDLESS OF WHETHER ORAL OR WRITTEN, EXPRESS OR IMPLIED, ALLEGEDLY ARISING FROM ANY USAGE OF ANY TRADE OR ANY COURSE OF DEALING, IN CONNECTION WITH THE USE OF INFORMATION CONTAINED HEREIN OR THE PRODUCT ITSELF.

revvity

Revvity, Inc.
940 Winter Street
Waltham, MA 02451 USA

(800) 762-4000
www.revvity.com

For a complete listing of our global offices, visit www.revvity.com
Copyright ©2023, Revvity, Inc. All rights reserved.